TREATMENT FOR OCULAR-RELATED DISORDERS
A treatment for ocular related disorders, such as macular degeneration, and preferably age-related macular degeneration, diabetic retinopathy, and diabetic macular edema is disclosed, using a compound of Formula I.
1 . A method of treating a patient for an ocular related disorder, wherein the method comprises administering to the patient a pharmaceutically effective amount of a compound of formula I,
or a pharmaceutically acceptable salt or prodrug thereof.
2 . The method of claim 1 , wherein the ocular related disorder is ocular neovascularization.
3 . The method of claim 2 , wherein the ocular related disorder is ocular neovascularization of the retina.
4 . The method of claim 1 , wherein the ocular related disorder is selected from: age related macular degeneration, diabetic retinopathy, and diabetic macular edema.
5 . The method of claim 4 , wherein the ocular disorder is age related macular degeneration.
6 . The method of claim 4 , wherein the ocular disorder is diabetic retinopathy.
7 . The method of claim 4 , wherein the ocular disorder is diabetic macular edema.
8 . The method of claim 1 , wherein the compound of formula I is administered to a patient who is concurrently being treated with ranizumab.
9 . A pharmaceutical composition for treating macular degeneration, diabetic retinopathy, or diabetic macular edema, comprising a compound of Formula I:
or a pharmaceutically acceptable salt or prodrug thereof.
10 . A method of treating macular degeneration, diabetic retinopathy, or diabetic macular edema, comprising: administering to a patient in need thereof a pharmaceutically effective amount of a Syk kinase inhibitor.